Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Growing evidence has confirmed that the prognosis of lung cancer is not only related to the stage of disease, but also to the physiological and psychological situation of the patients. Malignant tumors are often associated with weakness and cachexia, leading to less physical activities and worse moods. However, few studies that have attempted to investigate the impact of nutritional status on the prognosis of NSCLC. Existing applications of nutritional scoring systems in early-stage of NSCLC are very limited. Therefore, this study aims to observe the correlation between nutritional status and the prognosis of patients with early-stage NSCLC, to clarify the value in predicting the overall survival rate and progression-free survival rate of NSCLC patients, and to offer evidence for alleviating the social and economic burden of NSCLC.

Detailed Description
-----------------
The prognosis of lung cancer is not only related to the stage of disease, but also to the physiological and psychological situation of the patients. Malignant tumors are often associated with weakness and cachexia, leading to less physical activities and worse moods. However, few studies that have attempted to investigate the impact of nutritional status on the prognosis of NSCLC. Existing applications of nutritional scoring systems in early-stage of NSCLC are very limited. Therefore, this study aims to observe the correlation between nutritional status and the prognosis of patients with early-stage NSCLC, to clarify the value in predicting the overall survival rate and progression-free survival rate of NSCLC patients, and to offer evidence for alleviating the social and economic burden of NSCLC.

Official Title
-----------------
Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer (Stage IA to IIIA)

Conditions
-----------------
Sarcopenia, Non Small Cell Lung Cancer, Malnutrition

Intervention / Treatment
-----------------
* Device: Inbody 570
* Device: JAMAR Dynamometer
* Radiation: CT scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients with non-small cell lung cancer diagnosed by cytology or pathology meet the standards of clinical diagnosis and treatment guidelines for lung cancer of Chinese Medical Association (2018 Edition) TNM staging diagnosis of lung cancer meets the stage IA-IIIA Exclusion Criteria: Severe heart failure, acute progressive pulmonary inflammation, acute liver and kidney dysfunction in recent 2 weeks Incomplete clinical and follow-up data or disagreement or inability to conduct regular follow-up CT imaging evaluation A history of other malignant tumors and related tumor chemotherapy within half year, and previous history of radiotherapy Unable to walk, fail to complete the walking test, and the risk of fall down Unable to complete BIA examination due to pacemaker implantation and other reasons Withdraw from the study for any reasons

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Early-stage NSCLC with sarcopenia<br>Patients diagnosed with NSCLC meeting Stage IA-IIIA as well as sarcopenia by the enrollment | Device: Inbody 570<br>* Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up<br>Device: JAMAR Dynamometer<br>* Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up<br>Radiation: CT scan<br>* Chest and abdominal CT scan during each follow-up<br>|
| Early-stage NSCLC without sarcopenia<br>Patients diagnosed with NSCLC meeting Stage IA-IIIA but without sarcopenia by the enrollment | Device: Inbody 570<br>* Bioelectrical Impedance Analysis with Inbody 570 (Inbody Co., Seoul, Korea) during each follow-up<br>Device: JAMAR Dynamometer<br>* Handgrip strength measurement using a JAMAR Dynamometer (JAMAR Co., Ltd., USA) during each follow-up<br>Radiation: CT scan<br>* Chest and abdominal CT scan during each follow-up<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression free survival (PFS) | Time from diagnosis to clinically recorded disease progression or death from any cause | 2 years after enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival time (OST) | Outcome of patient death from diagnosis to any cause or the final follow-up time | 6, 12, 18 and 24 months after enrollment |